Results 211 to 220 of about 13,388,853 (301)

Efficacy and safety of imeglimin add-on to DPP-4 inhibitor therapy in Japanese patients with type 2 diabetes mellitus: An interim analysis of the randomised, double-blind FAMILIAR trial. [PDF]

Diabetes Obes Metab
Kaku K, Shimoda M, Osonoi T, Iwamoto M, Kaneto H.   +4 more
europepmc   +1 more source

Initiation of SGLT2 Inhibitors Versus DPP‐4 Inhibitors in Metformin Users and Risk of Incident Depression: A Nationwide, Claims‐Based Active‐Comparator New‐User Study

Diabetes, Obesity and Metabolism, Volume 28, Issue 11, Page 10765-10779, November 2026.
ABSTRACT Aims To examine the association between initiation of sodium‐glucose cotransporter‐2 (SGLT2) inhibitors and risk of incident depression compared with dipeptidyl peptidase‐4 (DPP‐4) inhibitors among adults with newly diagnosed Type 2 diabetes receiving metformin.
Sangwoo Park, Seogsong Jeong, Hye Jun Kim, Dae Ho Lee, Soo Jung Choi, Sang Min Park   +5 more
wiley   +1 more source

Synthesis and Anti-Diabetic Activity of an 8-Purine Derivative as a Novel DPP-4 Inhibitor in Obese Diabetic Zücker Rats. [PDF]

Drug Des Devel Ther
Chayah M, Luque-González A, Gómez-Pérez V, Salagre D, Al-Shdaifat A, Campos JM, Conejo-García A, Agil A.   +7 more
europepmc   +1 more source

Asymmetric Synthesis of a DPP-4 Inhibitor [PDF]

Synfacts, 2014
openaire   +1 more source

Genetic and Clinical Determinants of Variation in Drug Response in Type 2 Diabetes: Insights From the Scottish and UK Biobank Cohorts

Diabetes, Obesity and Metabolism, Volume 28, Issue 11, Page 10780-10794, November 2026.
ABSTRACT Objective Treatment response in type 2 diabetes (T2D) varies widely among individuals. This study aimed to quantify the contributions of clinical characteristics and genetic predisposition as measured through partitioned polygenic risk scores (pPRS) to variation in glycemic response to glucose‐lowering therapies.
S. Garg, R. Kitchen, R. Gupta, L. Donnelly, E. R. Pearson   +4 more
wiley   +1 more source

Effect of Imeglimin, a Novel Anti-Diabetic Agent, on Insulin Secretion and Glycemic Variability in Type 2 Diabetes Treated with DPP-4 Inhibitor: A 16-Week, Open Label, Pilot Study. [PDF]

Diabetes Metab Syndr Obes
Itsukaichi A, Yoshikawa F, Fuchigami A, Iwata Y, Sato G, Miyagi M, Hirose T, Uchino H.   +7 more
europepmc   +1 more source

DPP-4 Inhibitor-associated Bullous Pemphigoid in a Hemodialysis Patient. [PDF]

Intern Med, 2020
Usami J, Takezawa Y.
europepmc   +1 more source

Cardiorenal Mortality and Safety Outcomes of GLP‐1 Receptor Agonists in Type 2 Diabetes With BMI Below 27 kg/m2: A Target Trial Emulation

Diabetes, Obesity and Metabolism, Volume 28, Issue 11, Page 10498-10512, November 2026.
ABSTRACT Aims Cardiorenal evidence for glucagon‐like peptide‐1 receptor agonists (GLP‐1 RAs) derives mainly from trials in overweight or obesity; data in adults with Type 2 diabetes (T2D) and body mass index (BMI) below 27 kg/m2 are limited. Materials and Methods We emulated a target trial in the TriNetX US Collaborative Network (index dates 2020 to ...
Shao‐Chia Chen, Yu‐Nan Huang, Pei‐Yun Li, Jo‐Ching Chen, Gideon Meyerowitz‐Katz, Shun‐Fa Yang, Pen‐Hua Su   +6 more
wiley   +1 more source

DPP-4 inhibitor sitagliptin treatment results in altered myocardial metabolic proteome and oxidative phosphorylation in a swine model of chronic myocardial ischemia. [PDF]

Physiol Rep
Harris DD, Sabe SA, Broadwin M, Bellam K, Xu CM, Li JW, Abid MR, Sellke FW.   +7 more
europepmc   +1 more source

Possibility of pharmacokinetic drug interaction between a DPP-4 inhibitor and a SGLT2 inhibitor. [PDF]

Transl Clin Pharmacol, 2020
Gu N, Park SI, Chung H, Jin X, Lee S, Kim TE.   +5 more
europepmc   +1 more source